Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $548.7 million.

  • Allogene Therapeutics' Liabilities and Shareholders Equity fell 25.35% to $439.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 20.21%. This contributed to the annual value of $548.7 million for FY2024, which is 14.64% down from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' Liabilities and Shareholders Equity is $548.7 million, which was down 14.64% from $642.8 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Liabilities and Shareholders Equity peaked at $1.2 billion during FY2020, and registered a low of $548.7 million during FY2024.
  • Its 3-year average for Liabilities and Shareholders Equity is $671.0 million, with a median of $642.8 million in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first spiked by 71.05% in 2020, then declined by 21.82% in 2022.
  • Allogene Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $1.2 billion in 2020, then declined by 14.42% to $1.1 billion in 2021, then dropped by 21.82% to $821.6 million in 2022, then decreased by 21.76% to $642.8 million in 2023, then decreased by 14.64% to $548.7 million in 2024.